Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 392 of 5804
-
New drug cocktail aims to tame transplant complication
Disease control Not yet recruitingThis trial employs a single-arm, single-center design, planning to enroll 25 patients diagnosed with grade II-IV aGVHD at one center. Patients meeting all inclusion criteria and no exclusion criteria will be enrolled. After enrollment, all patients will receive Gecacitinib combin…
Phase: PHASE2 • Sponsor: Bin Gu • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Coffee for preemies? study tests caffeine to shield tiny kidneys
Prevention CompletedRecent observational data point towards a reduced incidence of acute kidney injury (AKI) with early caffeine use, but high-quality randomized controlled trials comparing early caffeine initiation to supportive therapy alone are lacking. This study aims to fill this critical gap b…
Phase: NA • Sponsor: Muhammad Aamir Latif • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
New drug aims to halt rare heart disease progression
Disease control Recruiting nowThe purpose of this study is to confirm that the treatment with acoramidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.
Phase: PHASE4 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for kids: drug may shield against dangerous viruses after transplant
Disease control Recruiting nowThis study investigates the impact of letermovir prophylaxis on viral infections (including CMV, EBV, BKV, HHV-6/7, RSV, ADV, HSV, etc.) following allogeneic hematopoietic stem cell transplantation in pediatric patients with EBV-associated T/NK-cell lymphoproliferative diseases a…
Phase: NA • Sponsor: Beijing Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for tough lymphoma: stem cell transplant trial for Non-Responders
Disease control Recruiting nowThis study is a multicenter, two-arm, prospective clinical trial, comprising two groups: the allogeneic hematopoietic stem cell transplantation group (Allo-HSCT) and the alternative salvage regimens. It aims to evaluate the efficacy and safety of Allo-HSCT and alternative salvage…
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Sound waves vs. shakes: can ultrasound tame essential tremor for years?
Disease control Recruiting nowThe goal of this observational study is to evaluate the long-term efficacy and safety of MR-guided focused ultrasound (MRgFUS) thalamotomy in patients with medication-refractory essential tremor. The main questions it aims to answer are: 1. Does MRgFUS thalamotomy provide susta…
Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Promising combo takes aim at Hard-to-Treat pancreatic cancer
Disease control OngoingThis prospective, multicenter clinical study evaluates the efficacy and safety of NALIRIFOX in combination with Stereotactic Body Radiation Therapy (SBRT) for patients with locally advanced unresectable pancreatic cancer. The primary endpoint is progression-free survival (PFS), w…
Phase: PHASE2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for advanced endometrial cancer: drug combo trial launches
Disease control Recruiting nowThe researchers are doing this study to find out whether elacestrant is an effective and safe treatment alone or in combination with abemaciclib for people with advanced or recurrent ER+ endometrial cancer.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for tough bladder cancer: immune drug plus chemo combo enters trial
Disease control Not yet recruitingThis open-label, randomised, multicentre, phase 2 study (OHAI-NMIBC-01) compares toripalimab plus sequential intravesical gemcitabine followed by mitomycin C (GEM→MMC) with toripalimab alone in adults with BCG-unresponsive or BCG-intolerant high-risk non-muscle-invasive bladder c…
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Magic mushroom therapy targets Cancer-Related anxiety in new trial
Symptom relief Recruiting nowThis study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. Who is it for? This study is for people who are aged between 18 and 80 years old and suffer from anxiety after adjustin…
Phase: PHASE2 • Sponsor: Psyence Australia Pty Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
New combo strategy takes on Hard-to-Treat breast cancer
Disease control Not yet recruitingThis is a phase II, multicentre, open-label, randomised controlled trial (patients are randomly assigned to one treatment arm or the other) evaluating two treatment strategies (sacituzumab govitecan and trastuzumab deruxtecan in an alternative schema or sacituzumab govitecan alon…
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 26, 2026 13:20 UTC
-
New drug MDX2004 targets advanced tumors in early trial
Disease control Recruiting nowThis study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advanced tumors.
Phase: PHASE1, PHASE2 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for Hard-to-Treat lymphoma: drug cocktail shows promise
Disease control Not yet recruitingThe goal of this phase 2 trial is to test the safety and efficacy of G-Pola-GemOx as induction therapy in patients with Refractory/Relapsed Aggressive B-Cell Lymphoma.
Phase: PHASE2 • Sponsor: Navy General Hospital, Beijing • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New inhaled antibody could help asthma sufferers breathe easier
Disease control Recruiting nowWhat is the goal of this study? The goal of this clinical trial is to find out whether the study drug LQ036 (a nebulized solution taken by inhaling through a nebulizer) works to improve lung function and asthma control in people whose asthma is not well controlled. The study will…
Phase: PHASE2 • Sponsor: Shanghai Novamab Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New 6-Month TB drug combo tested in diabetic patients
Disease control Not yet recruitingThe treatment of rifampicin-resistant/multidrug-resistant pulmonary tuberculosis (RR-TB) is characterized by a long treatment course, a high incidence of adverse reactions, a low cure rate, and a high recurrence rate. This is related to the large number of drugs in the RR-TB trea…
Sponsor: Wuhan Pulmonary Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug targets breast cancer in the brain
Disease control Not yet recruitingThis is a multi-center, open-label, two-cohort study. The purpose of this study is to evaluate the safety, tolerability and efficacy of SHR-A1811 in the treatment of HER2-positive breast cancer with brain and leptomeningeal metastases, and the efficacy and safety of SHR-A1811 in …
Phase: PHASE1, PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 26, 2026 17:54 UTC
-
New drug combo aims to fight tough lung cancer
Disease control Not yet recruitingThis is a single-arm, open-label, single-center phase II trial that will enroll 30 patients with limited-stage small-cell lung cancer to evaluate the safety and efficacy of adebrelimab combined with chemoradiotherapy followed by adebrelimab maintenance.
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
HIV drug combo may shield hearts: new trial launches
Disease control Recruiting nowThis randomized, open-label clinical trial will evaluate whether adding fostemsavir to current antiretroviral therapy can reduce the risk of cardiovascular disease in people with well-controlled HIV. Researchers will compare imaging, clinical and biomarker outcomes between partic…
Phase: PHASE2 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New hope for Moms-to-Be: safer malaria drugs tested in landmark trial
Disease control Recruiting nowThe SAFIRE study aims to find effective treatments with acceptable safety for malaria in early pregnancy, a particularly sensitive time for the adverse consequences of malaria in pregnancy for both mother and baby. Currently, WHO recommends the antimalarial drug artemether-lumefa…
Phase: PHASE3 • Sponsor: Liverpool School of Tropical Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can preventive surgery stop ovarian cancer in High-Risk women?
Prevention Recruiting nowThe goal of this multi-center observational study is to learn about the effectiveness and safety of different prophylactic (preventive) surgical options in women at moderate-to-high genetic risk for hereditary ovarian cancer (HOC). The main questions it aims to answer are: Does…
Sponsor: Peking University Third Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:08 UTC